Comparison · NCT03002038-87ea9c77
Azathioprine vs Rituximab: Number of Participants With Adverse Drug Reactions
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Azathioprine vs Rituximab: Number of Participants With Adverse Drug Reactions. Trial comparisons, record NCT03002038-87ea9c77. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03002038-87ea9c77
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0652 | 0.0224 | 0.175 | wilson | |
| Risk in group 2 | 0.1 | 0.0396 | 0.231 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0348 | -0.172 | 0.0906 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.652 | 0.155 | 2.74 | log | |
| Odds ratio, group 1 over group 2 | 0.628 | 0.132 | 2.99 | log | |
| Number needed to treat, for one fewer participant with the outcome on Azathioprine than on Rituximab | 28.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Azathioprine | Patients in this group will receive 50 mg of azathioprine, two times each day and gradually increased to maximum dose of 3 g daily with the aim of lymphocytes count less than 1500.~Azathioprine: Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose. | 3 | 46 | OG000 |
| Group 2 | Rituximab | Patients in this group will receive 1g of Rituximab in 500 cc normal saline serum through intravenous infusion with two weeks intervals (as one course) and each course of treatment is repeated every 6 months.~Rituximab: Patients will receive 1 g of Rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months. | 4 | 40 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- OTHER_PRE_SPECIFIED
- Title
- Number of Participants With Adverse Drug Reactions
- Description
adverse drug reactions will be observed closely and reported during the intervention. We will compare the number of adverse drug reactions in two groups. Also, adverse drug reactions will be described by details in each group.
- Time frame
- one year
- Population
- intention to treat analysis
Source ClinicalTrials.gov
Trial
- Title
- Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients
- NCT number
- NCT03002038
- Phases
- PHASE2, PHASE3
- Conditions
- Neuromyelitis Optica Spectrum Disorder
- Interventions
- Azathioprine, Rituximab
- Lead sponsor
- Isfahan University of Medical Sciences
- Results first posted
- 2020-09-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03002038?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03002038-87ea9c77